Impact of the spheroid model complexity on drug response

Journal of Biotechnology

Volumn 205, Issue , 2015, Pages 14-23

  Hoffmann, Oliver Ingo ^a   Ilmberger, Christian ^a   Magosch, Stefanie ^a   Joka, Mareile ^b   Jauch, Karl Walter ^b   Mayer, Barbara ^a,b  

^a Spherotec GmbH   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

Cancer cell line; Drug screening; Human tumor tissue; Spheroid model

Indexed keywords

CELLS; CYTOLOGY; DIAGNOSIS; DISEASES; DRUG THERAPY; FIBROBLASTS; MONOCLONAL ANTIBODIES; TISSUE; TUMORS;

CANCER CELL LINES; COMBINATION THERAPY; DRUG SCREENING; HUMAN TUMORS; MICROENVIRONMENTS; PHARMACEUTICAL DRUGS; RESPONSE PATTERNS; SCREENING MODELS;

CELL CULTURE;

ANTINEOPLASTIC AGENT; CAMPTOTHECIN; CETUXIMAB; EVEROLIMUS; FLUOROURACIL; HYDROXAMIC ACID; IRINOTECAN; OXALIPLATIN; PLATINUM COMPLEX; TRASTUZUMAB; VORINOSTAT;

ANALOGS AND DERIVATIVES; CACO 2 CELL LINE; CELL CULTURE; CELL SURVIVAL; COCULTURE; CYTOLOGY; DRUG EFFECTS; HCT116 CELL LINE; HT 29 CELL LINE; HUMAN; MULTICELLULAR SPHEROID; PROCEDURES; STROMA CELL; TREATMENT OUTCOME; TUMOR CELL CULTURE; TUMOR CELL LINE; TUMOR MICROENVIRONMENT;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CACO-2 CELLS; CAMPTOTHECIN; CELL LINE, TUMOR; CELL SURVIVAL; CELLS, CULTURED; CETUXIMAB; COCULTURE TECHNIQUES; EVEROLIMUS; FLUOROURACIL; HCT116 CELLS; HT29 CELLS; HUMANS; HYDROXAMIC ACIDS; ORGANOPLATINUM COMPOUNDS; SPHEROIDS, CELLULAR; STROMAL CELLS; TRASTUZUMAB; TREATMENT OUTCOME; TUMOR CELLS, CULTURED; TUMOR MICROENVIRONMENT;

EID: 84937043995     PISSN: 01681656     EISSN: 18734863     Source Type: Journal    
DOI: 10.1016/j.jbiotec.2015.02.029     Document Type: Article

References (53)

1. Abigerges D., Chabot G.G., Armand J.-P., Hérait P., Gouyette A., Gandia D. Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. J. Clin. Oncol. 1995, 13:210-221.
2. Alépée N., Bahinski T., Daneshian M., De Wever B., Fritsche E., Goldberg A., Hansmann J., Hartung T., Haycock J., Hogberg H., Hoelting L., Kelm J.M., Kadereit S., McVey E., Landsiedel R., Leist M., Lübberstedt M., Noor F., Pellevoisin C., Petersohn D., Pfannenbecker U., Reisinger K., Ramirez T., Rothen-Rutishauser B., Schäfer-Körting M., Zeilinger K., Zurich M.-G. State-of-the-art of 3D cultures (organs-on-a-chip) in safety testing and pathophysiology - a t4 report. ALTEX 2014, 10.14573/altex1406111.
3. Bang Y.-J., Van Cutsem E., Feyereislova A., Chung H.C., Shen L., Sawaki A., Lordick F., Ohtsu A., Omuro Y., Satoh T., Aprile G., Kulikov E., Hill J., Lehle M., Rüschoff J., Kang Y.-K. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010, 376:687-697.
4. Brattain M.G., Fine W.D., Khaled F.M., Thompson J., Brattain D.E. Heterogeneity of malignant cells from a human colonic carcinoma. Cancer Res. 1981, 41:1751-1756.
5. Chanmee T., Ontong P., Konno K., Itano N. Tumor-associated macrophages as major players in the tumor microenvironment. Cancers 2014, 6:1670-1690.
6. Colucci G., Gebbia V., Paoletti G., Giuliani F., Caruso M., Gebbia N., Cartenì G., Agostara B., Pezzella G., Manzione L., Borsellino N., Misino A., Romito S., Durini E., Cordio S., Di Seri M., Lopez M., Maiello E. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico dell'Italia Meridionale. J. Clin. Oncol. 2005, 23:4866-4875.
7. Correia A.L., Bissell M.J. The tumor microenvironment is a dominant force in multidrug resistance. Drug Resist. Updat. 2012, 15:39-49.
8. Van Cutsem E., Nordlinger B., Cervantes A. Advanced colorectal cancer: ESMO Clinical Practice Guidelines for treatment. Ann. Oncol. 2010, 21(Suppl. 5):v93-v97.
9. Das Thakur M., Pryer N.K., Singh M. Mouse tumour models to guide drug development and identify resistance mechanisms. J. Pathol. 2014, 232:103-111.
10. Deenen M.J., Klümpen H.-J., Richel D.J., Sparidans R.W., Wetermann M.J., Beijnen J.H., Schellens J.H.M., Wilmink J.W. Phase I and pharmacokinetic study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced solid malignancies. Invest. New Drugs 2012, 30:1557-1565.
11. De Roock W., Jonker D.J., Di Nicolantonio F., Sartore-Bianchi A., Tu D., Siena S., Lamba S., Arena S., Frattini M., Piessevaux H., Van Cutsem E., O'Callaghan C.J., Khambata-Ford S., Zaleberg J.R., Simes J., Karapetis C.S., Bardelli A., Tejpar S. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA 2010, 304:1812-1820.
12. Dexter D.L., Barbosa J.A., Calabresi P. N,N-dimethylformamide-induced alteration of cell culture characteristics and loss of tumorigenicity in cultured human colon carcinoma cells. Cancer Res. 1979, 39:1020-1025.
13. Fang W.B., Yao M., Cheng N. Priming cancer cells for drug resistance: role of the fibroblast niche. Front. Biol. (Beijing) 2014, 9:114-126.
14. Fujimoto S. Promising antitumor activity of a novel quinoline derivative, TAS-103, against fresh clinical specimens of eight types of tumors measured by flow cytometric DNA analysis. Biol. Pharm. Bull. 2007, 30(10):1923-1929.
15. Gaedtke L., Thoenes L., Culmsee C., Mayer B., Wagner E. Proteomic analysis reveals differences in protein expression in spheroid versus monolayer cultures of low-passage colon carcinoma cells. J. Proteome Res. 2007, 6:4111-4118.
16. Galon J., Mlecnik B., Bindea G., Angell H.K., Berger A., Lagorce C., Lugli A., Zlobec I., Hartmann A., Bifulco C., Nagtegaal I.D., Palmqvist R., Masucci G.V., Botti G., Tatangelo F., Delrio P., Maio M., Laghi L., Grizzi F., Asslaber M., D'Arrigo C., Vidal-Vanaclocha F., Zavadova E., Chouchane L., Ohashi P.S., Hafezi-Bakhtiari S., Wouters B.G., Roehrl M., Nguyen L., Kawakami Y., Hazama S., Okuno K., Ogino S., Gibbs P., Waring P., Sato N., Torigoe T., Itoh K., Satel P.S., Shukla S.N., Wang Y., Kopetz S., Sinicrope F.A., Scripcariu V., Ascierto P.A., Marincola F.M., Fox B.A., Pagès F. Towards the introduction of the 'Immunoscore' in the classification of malignant tumours. J. Pathol. 2014, 232:199-209.
17. Gaur S., Chen L., Ann V., Lin W.-C., Wang Y., Chang V.H.S., Hsu N.Y., Shia H.-S., Yen Y. Dovitinib synergizes with oxaliplatin in suppressing cell proliferation and inducing apoptosis in colorectal cancer cells regardless of RAS-RAF mutation status. Mol. Cancer 2014, 13:21.
18. Grünwald V., Rickmann M. Pharmacotherapy of solid tumors. New hopes and frustrations. Internist (Berl) 2014, 55:1220-1227.
19. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
20. Hanahan D., Coussens L.M. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 2012, 21:309-322.
21. Hayes S.A., Hudson A.L., Clarke S.J., Molloy M.P., Howell V.M. From mice to men: GEMMs as trial patients for new NSCLC therapies. Semin. Cell Dev. Biol. 2014, 27:118-127.
22. Herrera M., Herrera A., Domínguez G., Silva V., García J.M., Gómez I., Soldevilla B., Munoz C., Provencio M., Campos-Martin Y., García de Herreros A., Casal I., Bonilla F., Pena C. Cancer-associated fibroblast and M2 macrophage markers together predict outcome in colorectal cancer patients. Cancer Sci. 2013, 104:437-444.
23. Herrera M., Islam A.B.M.M.K., Herrera A., Martín P., García V., Silva J., Garcia J.M., Salas C., Casal I., García de Herreros A., Bonilla F., Pena C. Functional heterogeneity of cancer-associated fibroblasts from human colon tumors shows specific prognostic gene expression signature. Clin. Cancer Res. 2013, 19:5914-5926.
24. Huang L., Xu A., Liu S., Liu W., Li T.-J. Cancer-associated fibroblasts in digestive tumors. World J. Gastroenterol. 2014, 20:17804-17818.
25. Katz O.B., Shaked Y. Host effects contributing to cancer therapy resistance. Drug Resist. Updat. 2014, pii:S1368-7646(14)00080-6.
26. Kharaishvili G., Simkova D., Bouchalova K., Gachechiladze M., Narsia N., Bouchal J. The role of cancer-associated fibroblasts, solid stress and other microenvironmental factors in tumor progression and therapy resistance. Cancer Cell Int. 2014, 14:41.
27. Klemm F., Joyce J.A. Microenvironmental regulation of therapeutic response in cancer. Trends Cell Biol. 2014, pii:S0962-8924(14)00199-8.
28. Kyi C., Postow M.A. Checkpoint blocking antibodies in cancer immunotherapy. FEBS Lett. 2014, 588:368-376.
29. Labianca R., Nordlinger B., Beretta G.D., Mosconi S., Mandalà M., Cervantes A., Arnold D. Early colon cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2013, 24(Suppl. 6):vi64-vi72.
30. Linnekamp J.F., Wang X., Medema J.P., Vermeulen L. Colorectal cancer heterogeneity and targeted therapy: a case for molecular disease subtypes. Cancer Res. 2014, 75:245-249.
31. Lovitt C.J., Shelper T.B., Avery V.M. Advanced cell culture techniques for cancer drug discovery. Biology 2014, 3:345-367.
32. Luca A., Mersch S., Deenen R., Schmidt S., Messner I., Schäfer K.-L., Baldus S.E., Huckenbeck W., Piekorz R.P., Knoefel W.T., Krieg A., Stoecklein N.H. Impact of the 3D microenvironment on phenotype, gene expression, and EGFR inhibition of colorectal cancer cell lines. PLoS One 2013, 8:e59689.
33. Mahale J., Smagurauskaite G., Brown K., Thomas A., Howells L.M. The role of stromal fibroblasts in lung carcinogenesis: a target for chemoprevention?. Int. J. Cancer 2015, (in press).
34. Malaney P., Nicosia S.V., Davé V. One mouse, one patient paradigm: new avatars of personalized cancer therapy. Cancer Lett. 2014, 344:1-12.
35. Mallone R., Mannering S.I., Brooks-Worrell B.M., Durinovic-Belló I., Cilio C.m., Wong F.S., Schloot N.C., T-Cell Workshop Committee, Immunology of Diabetes Society Isolation and preservation of peripheral blood mononuclear cells for analysis of islet antigen-reactive T cell responses: position statement of the T-Cell Workshop Committee of the Immunology of Diabetes Society. Clin. Exp. Immunol. 2011, 163:33-49.
36. Mayer B., Klement G., Kaneko M., Man S., Jothy S., Rak J., Kerbel R.S. Multicellular gastric cancer spheroids recapitulate growth pattern and differentiation phenotype of human gastric carcinomas. Gastroenterology 2001, 121:839-852.
37. McMillin D.W., Negri J.M., Mitsiades C.S. The role of tumour-stromal interactions in modifying drug response: challenges and opportunities. Nat. Rev. Drug Discov. 2013, 12:217-228.
38. Mink S.R., Vashistha S., Zhang W., Hodge A., Agus D.B., Jain A. Cancer-associated fibroblasts derived from EGFR-TKI-resistant tumors reverse EGFR pathway inhibition by EGFR-TKIs. Mol. Cancer Res. 2010, 8:809-820.
39. Mitchem .B., Brennan D.J., Knolhoff B.L., Belt B.A., Zhu Y., Sanford D.E., Belaygorod L., Carpenter D., Collins L., Piwnica-Worms D., Hewitt S., Udupi G.M., Gallagher W.M., Wegner C., West B.L., Wang-Gillam A., Goedegebuure S.P., Linehan D.C., DeNardo D.G. Targeting tumor-infiltrating macrophages decreases tumorinitiating cells, relieves immunosuppression and improves chemotherapeutic responses. Cancer Res. 2013, 73:1128-1141.
40. Pernot S., Terme M., Voron T., Colussi O., Marcheteau E., Tartour E., Taieb J. Colorectal cancer and immunity: what we know and perspectives. World J. Gastroenterol. 2014, 20:3738-3750.
41. Ramalingam S.S., Parise R.A., Ramananthan R.K., Lagattuta T.F., Musguire L.A., Stoller R.G., Potter D.M., Argiris A.E., Zwiebel J.A., Egorin M.J., Belani C.P. Phase I and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies. Clin. Cancer Res. 2007, 13:3605-3610.
42. Rolfo C., Bronte G., Sortino G., Papadimitriou K., Passiglia F., Fiorentino E., Marogy G., Russo A., Peeters M. The role of targeted therapy for gastrointestinal tumors. Expert Rev. Gastroenterol. Hepatol. 2014, 8:875-885.
43. Santin A.D., Hermonat P.L., Ravaggi A., Bellone S., Roman J.J., Smith C.V., Pecorelli S., Radominska-Pandya A., Cannon M.J., Parham G.P. Phenotypic and functional analysis of tumor-infiltrating lymphocytes compared with tumor-associated lymphocytes from ascitic fluid and peripheral blood lymphocytes in patients with advanced ovarian cancer. Gynecol. Obstet. Invest. 2001, 51:254-261.
44. Santoni M., Massari F., Amantini C., Nabissi M., Maines F., Burattini L., Berardi R., Santoni G., Montironi R., Tortora G., Cascinu S. Emerging role of tumor-associated macrophages as therapeutic targets in patients with metastatic renal cell carcinoma. Cancer Immunol. Immunother. 2013, 62:1757-1768.
45. Schüll B., Scheithauer W. Raltitrexed and oxaliplatin in colorectal cancer: in vitro and in vivo study of a synergistic cytostatic combination. Acta Med. Austriaca 2002, 29:124-131.
46. Semple T.U., Quinn L.A., Woods L.K., Moore G.E. Tumor and lymphoid cell lines from a patient with carcinoma. Cancer Res. 1978, 38:1345-1355.
47. Sorich M.J., Wiese M.D., Rowland A., Kichenadasse G., McKinnon R.A., Karapetis C.S. Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized controlled trials. Ann. Oncol. 2014, pii:mdu378.
48. Tampakis A., Tampaki E.C., Nebiker C.A., Kouraklis G. Histone deacetylase inhibitors and colorectal cancer: what is new?. Anticancer Agents Med. Chem. 2014, 14:1220-1227.
49. Tan A.R., Moore D.F., Hidalgo M., Doroshow J.H., Poplin E.A., Goodin S., Mauro D., Rubin E.H. Pharmacokinetics of cetuximab after administration of escalating single dosing and weekly fixed dosing in patients with solid tumors. Clin. Cancer Res. 2006, 12:6517-6522.
50. Tournigand C., André T., Achille E., Lledo G., Flesh M., Mery-Mignard D., Quniaux E., Couteau C., Buyse M., Ganem G., Landi B., Colin P., Louvet C., de Gramont A. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J. Clin. Oncol. 2004, 22:229-237.
51. Xu X., Farach-Carson M.C., Jia X. Three-dimensional in vitro tumor models for cancer research and drug evaluation. Biotechnol. Adv. 2014, pii:S0734-9750(14)00114-1.
52. Yang C., He L., He P., Liu Y., Wang W., He Y., Du Y., Gao F. Increased drug resistance in breast cancer by tumor-associated macrophages through IL-10/STAT3/bcl-2 signaling pathway. Med. Oncol. 2015, 32:352.
53. Zhang J., Liu J. Tumor stroma as targets for cancer therapy. Pharmacol. Ther. 2013, 137:200-215.